NOOMO1
 

ABOUT US

NomoCan Pharmaceuticals offers First-in-Class targeted therapies for some of the most aggressive cancers with unmet medical need. Our platform technology not only makes available a selective and specific diagnostic and prognostic test for early detection, but more remarkably, it introduces a highly effective monoclonal antibody (mAb) drugs for the treatment of various cancers in order to “Bring Hope” to patients affected by this devastating disease.​

Bring Hope

PIPELINE

NMC-001

NMC-001 monoclonal antibody targets a specific pancreatic cancer marker and is able to selectively identify and diagnose pancreatic cancer in human. With a high affinity for its target, NMC-001 demonstrates potent anti-tumor efficiency in rodent models of pancreatic cancer. 

53,670

New Cases of

Pancreatic Cancer

diagnosed in 2017

43,090

Estimated Deaths of

Pancreatic Cancer

in 2017

8.2%

5-Year Survival 

 
 

TEAM

Ehsan S. Yazdi, Ph.D., M.P.H.

Co-Founder & Chief Executive Officer

Kamyar Neshvadian, M.S., F.R.M.

Co-Founder & Chief Financial Officer

Jahanara Ali, Ph.D.

Chief Business Development Officer

Jean Paul Thiery, Ph.D.

Chief Scientific Officer

Lei Zhang, M.D.

Chief Clinical & Regulatory Officer

Owen O'Connor, M.D., Ph.D.

Board of Directors , Member 

 
 

CONTACT

For more information, please contact us below.
Our Address

NomoCan Pharmaceuticals LLC

310 E 67th Street, Suite 1-45

New York, NY 10065

© 2017 NomoCan All Rights Reserved.